Let's talk
Contact us
Drug Discovery at BioDuro (Icon)


Comprehensive studies that elucidate pharmacodynamics, mechanism of action, and efficacy of candidate compounds. In vivo and in vitro studies are conducted with utmost care and compliance with best industry practice.

Interested in our Pharmacology expertise?

Contact us


BioDuro’s pharmacology team has extensive drug discovery and development experience in the pharmaceutical industry enabling us to support fully integrated programs, including study design and data interpretation. Special expertise in metabolic and inflammatory diseases is coupled with a commitment to working with clients to develop customized models to address specific needs of drug discovery programs.

BioDuro Advantage

  • Scientific staff with a broad range of expertise
  • Cost effective
  • Versatility in animal handling, dosing and surgery
  • High quality and timely delivery of end point results


  • In vivo efficacy evaluation
  • Immunology and Inflammation animal models
  • Metabolic diseases animal models
  • Liver and Renal diseases models
  • PK/PD and histology studies
  • Cellular and biomarker analyses

Inflammation and Immunology Disease


Metabolic Diseases / NASH

Metabolic Diseases Animal Models

  • High fat diet induced obese (DIO) rats/mice
  • Streptozotocin (STZ) induced type 1 diabetic rats/mice
  • High fat diet (HFD) + STZ induced type 2 diabetic rats/mice
  • KKAy mice with T2D complications such as retinopathy & nephropathy
  • ob/ob and db/db mice
  • Myocardial infarction and reperfusion injury in rats/mice
  • Renal ischemia and reperfusion injury in rats/mice

In Vivo Assays

  • Oral/intraperitoneal glucose, insulin and pyruvate tolerance tests
  • Glucagon challenge tests
  • Energy expenditure indirect calorimetry system (TSE)
  • Food intake and water intake monitoring
  • Urine and feces collection
  • Insulin level detection
  • Body fat and water composition by echoMRI


BioDuro’s pharmacology team has developed highly clinically translatable animal NASH models to evaluate drug candidates. With short NASH induction periods of 12 – 16 weeks in mice and 8 – 12 weeks in hamsters our NASH models successfully mimic the pathogenesis of clinical NASH patients and exhibit hallmarks of NASH, including steatosis, lobular inflammation, ballooning and fibrosis.

  • Clinical Relevance
    • Obesogenic NASH models featuring all the major indicators of NAFLD to moderate NASH, including dyslipidemia, inflammation, ballooning and robust fibrosis.
    • Pharmacologic responses
      • Reference compounds (OCA, Elafibrinor, Semaglutide) in our high fat diet + modified high fat diet (HFD+mHFD) NASH mouse model match the responses of these experimental drugs in clinical trials
    • Histology and biomarkers
      • Demonstrate clinically relevant levels of disease phenotype & scores.
      • Includes steatosis, ballooning, inflammation, mallory body and fibrosis
    • Metabolic profiles
      • Similarly altered obesity markers as does human NASH, including insulin, glucose, cholesterol, triglycerides and free fatty acid.
    • Mechanisms of action
      • Drugs targeting diverse biological pathways and processes
    • Speed
      • High fat diet + modified high fat diet (HFD + mHFD) mouse model with shorter induction period between 12 – 16 weeks
      • High fat, high cholesterol + Fructose (HFC+F) hamster models with induction period between 8 – 12 weeks
    • Comprehensive
      • 5 different NASH disease models
      • Multiple induction methods:
        • Obesogenic (HFD, mHFD, AMLN)
        • Chemical induction (CCl4, AMLN+CCl4)
        • Nutrient deficient (0.1MCD)
    • Collaborative & Responsive
      • Group leaders & study directors provide rapid feedbacks and consultations to your preclinical model studies, including model selection, study design and data interpretation

NASH Models

  • NAFLD/NASH Models & in Vitro Assays
    • Nutrient-deficient NASH Models
      • SD rat or C57bl mice fed on MCD diet for 1-2 weeks
      • SD rat or C57bl mice fed on 0.1MCD diet for 2-6 weeks
    • Chemically induced NASH Models
      • AMLN/HFD + CCl4 in C57bl mice, 12+4 weeks
      • Featured with inflammation, steatohepatitis and fibrosis
    • Obesogenic dietary NASH Models
      • HFD + modified HFD/WD in C57bl mice, 12-16 weeks
    • Genetic NASH Models
      • ob/ob mice with AMLN diet, 8-12 weeks
    • Hamster NASH Model
      • Golden Syrian hamsters
      • High fat & high cholesterol (HFC) plus fructose, 8-12 weeks
    • Fatty Liver
      • Liver weight
      • Liver Function: ALT, AST
      • Lipid panel (liver & serum): TC, TG, FFA
      • Insulin resistance: Insulin, BG
      • Histology: HE
    • Hepatic Fibrosis markers
      • Collagen type 1a, 3a, α-1 Procollagen
      • SMA-a, TGF-b
      • Hydroxyproline
      • Histology Sirius Red staining
    • Hepatic Inflammation markers
      • TNF-a levels
      • Mononuclear cell infiltration
      • Oxidative Stress:
        • Reactive oxygen species
        • Hydroxynonenal (HNE) levels



  • Mouse/rat BBB
  • Formalin-induced nociceptive response (Pain) model
Interested in our expertise?
Contact us for more information Get in touch